John F. Paolini - Nov 7, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Nov 7, 2022
Transactions value $
-$377,715
Form type
4
Date filed
11/9/2022, 03:16 PM
Previous filing
Sep 6, 2022
Next filing
Mar 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $52.7K +28.4K +78.04% $1.86* 64.7K Nov 7, 2022 Direct F1
transaction KNSA Class A Common Share Sale -$430K -28.4K -43.83% $15.18 36.3K Nov 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -28.4K -14.35% $0.00 169K Nov 7, 2022 Class A Common Share 28.4K $1.86 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.00 to $15.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 The option is fully vested and exercisable.